Premium
Tissue and blood protozoa including toxoplasmosis, Chagas disease, leishmaniasis, Babesia , Acanthamoeba , Balamuthia , and Naegleria in solid organ transplant recipients— Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice
Author(s) -
La Hoz Ricardo M.,
Morris Michele I.
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13546
Subject(s) - medicine , intensive care medicine , protozoan infection , toxoplasmosis , immunology , acanthamoeba , chagas disease , organ transplantation , trypanosoma cruzi , miltefosine , transmission (telecommunications) , guideline , toxoplasma gondii , transplantation , leishmaniasis , virology , visceral leishmaniasis , pathology , biology , microbiology and biotechnology , parasite hosting , electrical engineering , world wide web , computer science , engineering , antibody
Abstract These updated guidelines from the Infectious Diseases Community of Practice of the American Society of Transplantation review the diagnosis, prevention, and management of tissue and blood protozoal infections in the pre‐ and post‐transplant period. Significant new developments in the field have made it necessary to divide the previous single guideline published in 2013 into two sections, with the intestinal parasites separated from this guideline devoted to tissue and blood protozoa. The current update reflects the increased focus on donor screening and risk‐based recipient monitoring for parasitic infections. Increased donor testing has led to new recommendations for recipient management of Toxoplasma gondii and Trypanosoma cruzi . Molecular diagnostics have impacted the field, with access to rapid diagnostic testing for malaria and polymerase chain reaction testing for Leishmania . Changes in Babesia treatment regimens in the immunocompromised host are outlined. The risk of donor transmission of free‐living amebae infection is reviewed. Changing immigration patterns and the expansion of transplant medicine in developing countries has contributed to the recognition of parasitic infections as an important threat to transplant outcomes. Medications such as benznidazole and miltefosine are now available to US prescribers as access to treatment of tissue and blood protozoa is increasingly prioritized.